Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), reducing blood vessel growth through reduction ...

2016年1月7日 · We designed the study to derive and validate a cutoff point of the sFlt-1:PlGF ratio for the prediction of the short-term absence or presence of preeclampsia, in a two-phase approach...

sFlt-1 (sVEGFR-1) is an antiangiogenic factor expressed as an alternatively spliced variant of VEGFR-1 that lacks both the transmembrane and cytoplasmic domains. sFlt-1 binds VEGF and PlGF and blocks their angiogenic effects on VEGFR. sFlt-1 may also form a heterodimer with the surface membrane VEGFR-1 and inhibit its postreceptor signaling ...

2021年8月15日 · One driving factor for developing preeclampsia—a pregnancy disorder, often associated with poor spiral artery (SpA)-remodeling and fetal growth restriction—is the anti-angiogenic sFLT1 (soluble fms-like tyrosine kinase-1), which is found to be highly upregulated in preeclampsia patients.

The anti-angiogenic factor, soluble fms-like tyrosine kinase 1 (sFlt-1) and the pro-angiogenic factor, placental growth factor (PlGF), can be measured in plasma and serum and are usually reported as a ratio, which specifically relates to the onset and severity of preeclampsia.

2020年7月27日 · Preeclampsia is characterized by angiogenic imbalance (AI), sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) is useful for its diagnosis and prediction of adverse outcomes...

2025年2月18日 · sFlt-1 and PlGF are key biomarkers in the formation of blood vessels during pregnancy. However, an angiogenic imbalance of these key biomarkers has been proven to play an important role in the development of preeclampsia.

The Elecsys® sFlt-1/PlGF ratio is an FDA-cleared test that provides objective data to complement standard clinical assessment and laboratory evaluation in risk stratification for preeclampsia with severe features.

Recently, sFlt-1 has emerged as a new marker for early diagnosis and disease surveillance of angiogenesis-related diseases. However, few comprehensive reviews focus on the relationship between sFlt-1 and related diseases despite that many results have yielded.

Soluble fms-like tyrosine kinase-1 (sFlt-1) is a vascular endothelial growth factor and antagonist of placental growth factor (PlGF) that causes vasoconstriction and endothelial damage,...